- Reaction of ethyl 4,4,4-trifluoroacetoacetate enolate with 3-bromo-1,1,1-trifluoroacetone: Synthesis of 2,4-bis (trifluoromethyl) furan
-
The potassium enolate of ethyl 4,4,4-trifluoroacetoacetate 1 reacts with 3-bromo-1,1,1-trifluoroacetone 2 in DMSO solution to yield three products. Ethyl 2,4-bis(trifluoromethyl)-4-hydroxydihydro-3-furoate 3 is generated via C-acylation. The hydrated trifluoromethyl ketone 4 is formed by O-alkylation and 4 reacts further with 2 to give the di-O-alkylated ketone hydrate 5. Compound 3 undergoes dehydration to the furan derivative 6 on reaction with Ac2O-ZnCl2.
- Smith, Jonathan O.,Mandal, Braja K.,Filler, Robert,Beery, James W.
-
-
Read Online
- Discovery of Novel Inhibitors of Uridine Diphosphate- N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients
-
Pseudomonas aeruginosa is of major concern for cystic fibrosis patients where this infection can be fatal. With the emergence of drug-resistant strains, there is an urgent need to develop novel antibiotics against P. aeruginosa. MurB is a promising target
- Abell, Chris,Blundell, Tom L.,Brown, Karen P.,Coyne, Anthony G.,Di Pietro, Ornella,Floto, R. Andres,Hess, Jeannine,Holland, Matthew T. O.,Kim, So Yeon,Marchetti, Chiara,Mendes, Vitor,Acebrón-García-De-Eulate, Marta,Mayol-Llinàs, Joan
-
p. 2149 - 2173
(2022/02/14)
-
- PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS
-
The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The p
- -
-
Paragraph 00335; 00348
(2014/05/24)
-
- AMINOETHANOL DERIVATIVES
-
The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
- -
-
Page/Page column 125
(2010/11/30)
-
